Kristine Peregrino Lacuna

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Therapeutic advances in leiomyosarcoma”.

Therapeutic advances in leiomyosarcoma

Frontiers in Oncology(2023)10.3389/fonc.2023.1149106

N/A

0DataRank · unranked

49 citations

Sminu Bose, Matthew Ingham, Gary K. Schwartz, Kristine Peregrino Lacuna

Alliance A092104: A randomized phase 2/3 study of olaparib plus temozolomide versus investigator’s choice for the treatment of patients with advanced uterine leiomyosarcoma after progression on prior chemotherapy.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps11584

N/A

0DataRank · unranked

2 citations

Sumithra J. Mandrekar, Jacob B. Allred, Stephanie Berg, Martee L. Hensley, Brian Andrew Van Tine +4 more

ETCTN/NCI 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for the treatment of unresectable and metastatic conventional chondrosarcoma.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.11531

N/A

0DataRank · unranked

1 citations

Shing M. Lee, Liner Ge, Mihaela Druta, Anthony P. Conley, Mary Louise Keohan +14 more